Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
Hillhouse Capital has agreed to buy George Clinical, an Australia-based clinical research organisation (CRO) with a global footprint, for an undisclosed sum.
SuZhou LavaMed, a China-based medical devices manufacturer, has raised USD 40m in angel and Series A funding from Zhejiang Silk Road Fund, Junshang Capital, and Lilly Asia Ventures (LAV).
Hong Kong’s E15 VC has hit a first close of USD 60.75m on its third global deep tech fund with an anchor investment from existing cornerstone LP Sun Hung Kai & Co (SHK).
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
Safe Pharmaceutical Research Institute, a Beijing-based clinic research organization (CRO) focused on novel drugs, has raised a CNY500m (USD 71m) Series D round led by SDIC Venture Capital and China State-owned Venture Capital Fund.
A Chinese investor group featuring several private equity firms has sold the non-China assets of LifeStyles Healthcare, a global sexual health and wellness platform best known for the Lifestyles condom brand, to US-based Linden Capital Partners.
Swee Yeok Chu, CEO and president of Singapore government investor EDBI, is stepping down from her role with a view to launching her own fund.
Targeting PRP Diagnostic Imaging through its long-hold fund meant IFM Investors could offer the company stability and partnership. It expects to generate dividend yield and capital growth
Having raised its second fund amid weakening investor sentiment for biotech, Panacea Venture expects deployment to be guided by a widening valuation gap between the US and China
Investors are increasingly challenged to reconcile a vanishing divide between some infrastructure and PE strategies, the AVCJ Private Equity & Venture Forum heard.
Panacea Venture, a healthcare-focused investment firm established by James Huang, formerly a partner at KPCB China, has closed its second fund with approximately USD 276m in commitments.
Bertelsmann Investments, Shinhan Venture investment, Mars Growth and Vertex Ventures Southeast Asia & India have participated in a USD 28m pre-Series B round for Singapore virtual healthcare platform Speedoc.
Investcorp has led a INR 5.45bn (USD 66.7m) investment in Global Dental Services (GDS), an India-based dental clinic chain that claims to be the largest business of its type in Asia and one of the top 15 globally.
Giant Biogene, a China-based producer of skin treatments that use bioactive ingredients, gained nearly 10% on debut following a HKD 549.4m (USD 70m) Hong Kong IPO.
NSSK found a rare succession-driven special situations deal in Japan’s prosperous healthcare space with pharmacy operator Kraft. It is the eight-year-old private equity firm’s largest deal to date
TPG has completed its acquisition of a majority stake in Australia-based prescription medicines business iNova Pharmaceuticals, facilitating exits for Pacific Equity Partners (PEP) and The Carlyle Group.
India’s Jashvik Capital, a private equity firm set up by Naresh Patawari, formerly a partner at TA Associates, has achieved a first close of undisclosed size on its debut fund. The target is USD 350m.
Adverse fundraising conditions didn’t deter deal-by-deal player Elevation Private Equity from investing in Korea healthcare turnaround, and by extension, aligning with a key domestic partner
Singapore’s AUM Biosciences, a VC-backed oncology treatments developer, has agreed to a NASDAQ listing via special purpose acquisition company (SPAC) at a pre-money equity valuation of USD 400m.
Warburg Pincus’ investment in Chinese medical devices industry services provider HTDK Group is riding the domestic healthcare wave. Bringing foreigners to the party is the next chapter
Japanese middle-market private equity firm NSSK has acquired 100% of Kraft, a local pharmacy chain that operates under the Sakura brand, for an undisclosed sum.
Guangzhou-based gene delivery company VectorBuilder has raised a CNY 410m (USD 57m) Series C round led by Legend Capital, Sui Kai Equity Investment, and Yuexiu Industrial Fund.